A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Aclidinium bromide (Primary) ; Aclidinium bromide/formoterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms AVANT
- Sponsors AstraZeneca
- 03 Nov 2017 Planned End Date changed from 12 Dec 2018 to 29 Mar 2019.
- 03 Nov 2017 Planned primary completion date changed from 12 Dec 2018 to 29 Mar 2019.
- 04 Aug 2017 Planned End Date changed from 1 Nov 2018 to 12 Dec 2018.